ABSTRACT
No disponible
Subject(s)
Humans , Male , Middle Aged , Ustekinumab/adverse effects , Nephrotic Syndrome/chemically induced , Nephrotic Syndrome/diagnosis , Psoriasis/drug therapy , Ustekinumab/therapeutic useABSTRACT
No disponible
Subject(s)
Humans , Male , Young Adult , Paralysis/complications , Paralysis/diagnosis , Hypokalemia/complications , Hypokalemia/diagnosis , Thyroiditis, Autoimmune/complications , Thyroiditis, Autoimmune/diagnosis , Quadriplegia/complications , Quadriplegia/diagnosis , Potassium Chloride/therapeutic use , Thyroxine/therapeutic use , Electrocardiography , Mutagenesis/genetics , Thyroiditis, Autoimmune/physiopathology , Thyrotoxicosis/complications , Thyrotoxicosis/diagnosis , Endocrine System Diseases/complications , Endocrine System Diseases/diagnosisABSTRACT
Las patologías reumatológicas, y en primer lugar la artritis reumatoidea (AR), siguen siendo unas de las principales causas de amiloidosis secundaria. La aparición de agentes biológicos como el adalimumab en el tratamiento precoz de la AR puede ser una alternativa eficaz para frenar el desarrollo y la progresión de la amiloidosis secundaria. No todos los pacientes responderán igual al tratamiento; debemos considerar la comorbilidad asociada, los factores de mal pronóstico para predecir la repuesta terapéutica y los posibles efectos adversos. Dentro de los efectos adversos de las terapias biológicas, hay que destacar el aumento de la tasa de infecciones letales y cuadros de insuficiencia cardíaca. Presentamos dos casos clínicos con amiloidosis renal secundaria a AR que han seguido un curso clínico diferente: nuestro primer caso tuvo una buena repuesta al adalimumab, mientras que el segundo caso evolucionó desfavorablemente después del inicio del tratamiento, falleciendo por complicaciones cardiovasculares (AU)
Rheumatological diseases and, firstly, rheumatoid arthritis (RA) remain a major cause of secondary amyloidosis. The emergence of biological agents such as adalimumab in the early treatment of RA can be an effective alternative to stop the development and progression of secondary amyloidosis. Not all patients will respond the same way to treatment; we must consider associated comorbidity, the poor prognosis factors for predicting therapeutic response and possible adverse effects. In the adverse effects of biological therapies, there has been an increase in the rate of lethal infections and congestive heart failure. We present two cases with renal amyloidosis secondary to RA who had a different clinical course: our 1st case had a good response to Adalimumab while the 2nd case evolved unfavourably after treatment, and died from cardiovascular complications (AU)
Subject(s)
Humans , Female , Middle Aged , Aged , Arthritis, Rheumatoid/complications , Amyloidosis/drug therapy , Antibodies, Monoclonal/therapeutic use , Amyloidosis/etiology , Risk Factors , Biological TherapyABSTRACT
Rheumatological diseases and, firstly, rheumatoid arthritis (RA) remain a major cause of secondary amyloidosis. The emergence of biological agents such as adalimumab in the early treatment of RA can be an effective alternative to stop the development and progression of secondary amyloidosis. Not all patients will respond the same way to treatment; we must consider associated comorbidity, the poor prognosis factors for predicting therapeutic response and possible adverse effects. In the adverse effects of biological therapies, there has been an increase in the rate of lethal infections and congestive heart failure. We present two cases with renal amyloidosis secondary to RA who had a different clinical course: our 1st case had a good response to Adalimumab while the 2nd case evolved unfavourably after treatment, and died from cardiovascular complications.
